Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
33.56 USD | +3.36% | +3.55% | +55.95% |
Apr. 19 | Sector Update: Health Care Stocks Steady Pre-Bell Friday | MT |
Apr. 19 | Spyre Therapeutics Files Mixed-Securities Shelf Registration for About 33.4 Million Shares | MT |
Financials (USD)
Sales 2024 * | 6.82M | Sales 2025 * | 5.17M | Capitalization | 1.19B |
---|---|---|---|---|---|
Net income 2024 * | -169M | Net income 2025 * | -167M | EV / Sales 2024 * | 80.8 x |
Net cash position 2024 * | 638M | Net cash position 2025 * | 333M | EV / Sales 2025 * | 166 x |
P/E ratio 2024 * |
-9.22
x | P/E ratio 2025 * |
-11.3
x | Employees | 30 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 87.42% |
Latest transcript on Spyre Therapeutics, Inc.
1 day | +3.36% | ||
1 week | +0.80% | ||
Current month | -11.52% | ||
1 month | -9.30% | ||
3 months | +21.24% | ||
6 months | +214.82% | ||
Current year | +55.95% |
Managers | Title | Age | Since |
---|---|---|---|
Cameron Turtle
CEO | Chief Executive Officer | 34 | 23-06-21 |
Scott Burrows
DFI | Director of Finance/CFO | 47 | 23-08-31 |
Brian Connolly
CTO | Chief Tech/Sci/R&D Officer | - | Nov. 26 |
Members of the board | Title | Age | Since |
---|---|---|---|
Tomas Kiselak
BRD | Director/Board Member | 38 | 23-06-21 |
Russell Cox
CHM | Chairman | 60 | 15-05-31 |
Jeffrey Albers
BRD | Director/Board Member | 52 | Nov. 26 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 33.56 | +3.36% | 225,965 |
24-04-25 | 32.47 | -1.58% | 233,608 |
24-04-24 | 32.99 | -3.68% | 203,860 |
24-04-23 | 34.25 | +2.87% | 201,520 |
24-04-22 | 33.3 | +2.73% | 261,723 |
Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+55.95% | 1.19B | |
-2.31% | 103B | |
+0.56% | 95.71B | |
+1.69% | 22.02B | |
-17.37% | 20.9B | |
-9.30% | 17.85B | |
-41.01% | 16.21B | |
-14.85% | 15.52B | |
+3.21% | 13.86B | |
+33.54% | 12.04B |
- Stock Market
- Equities
- SYRE Stock